Stief CG, Gratzke C. The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle. Am J Physiol Renal Physiol 305: F1383-F1390, 2013. First published September 18, 2013 doi:10.1152/ajprenal.00380.2013.-Inhibition of prostate smooth muscle contraction is an important strategy for medical treatment of lower urinary tract symptoms (LUTS). Besides ␣ 1-adrenoceptors, prostate smooth muscle contraction is induced by activation of thromboxane (TXA2) receptors (TXA2-R). Here, we examined the effects of the TXA2-R antagonist picotamide on contraction of human prostate tissue. Prostate tissues were obtained from radical prostatectomy. The effects of picotamide (300 M), L-665,240 (3 M), and seratrodast (3 M) on U46619-, electric field stimulation-(EFS-), phenylephrine-, and norepinephrine-induced contractions were studied in organ baths. Expression of TXA2-R and TXA2 synthase (TXS) was examined by fluorescence stainings. Picotamide, seratrodast, and L-655,240 inhibited concentration-dependent contractions induced by the TXA2 analog U46619. Picotamide, but not seratrodast or L-655,240, inhibited frequency-dependent contractions induced by EFS. Picotamide inhibited concentration-dependent contractions induced by norepinephrine or by the selective ␣ 1-adrenoceptor agonist phenylephrine. In prostate strips, where only submaximal contraction by a low dose of phenylephrine was induced, application of U46619 raised tone to maximum phenylephrine-induced tension. Immunoreactivity for TXA2-R and TXS was observed in the stroma and in epithelial cells of glands. Colocalization of both immunoreactivites was observed with the smooth muscle markers calponin and ␣-smooth muscle actin, with the epithelial marker pan-cytokeratin, and with prostate-specific antigen in the stroma and glands. The receptor antagonist picotamide inhibits ␣ 1-adrenergic, TXA2-mediated, and EFS-induced contractions in the human prostate. To the best of our knowledge, this is the first antagonist able to inhibit two different contraction systems in the prostate.
PROSTATE SMOOTH MUSCLE TONE is an important target for therapy of lower urinary tract symptoms (LUTS) in patients with benign prostate syndrome (BPS; Refs. 2, 3, 17, 27, 28) . Treatment with ␣ 1 -adrenoceptor blockers (␣ 1 -blockers) causes relaxation of prostate smooth muscle and improves symptoms (2, 3, 17, 27, 28) . Nevertheless, medical treatment of LUTS remains a challenge, as current therapeutic options are insufficient. Indeed, in clinical studies the benefit from ␣ 1 -blockers is limited (9, 10, 16, 18) . This suggests a contribution of nonadrenergic mediators to smooth muscle tone in BPS in addition to ␣ 1 -adrenoceptors.
Thromboxane A2 (TXA2) has been shown to induce contraction of human prostate smooth muscle by activation of TXA2 receptors (TXA2-R) in the prostate stroma (32) . TXA2 is produced by the TXA2 synthase (TXS; Refs. 21, 30) . TXS and endogenous TXA2 were both detected in human prostate tissue (32) . Of note, TXA2-Rs share identical intracellular effectors with ␣ 1 -adrenoceptors to induce contraction: both receptors use Rho kinase and calcium-dependent mechanisms for contraction of prostate smooth muscle (3, 7, 32) . This might explain why ␣ 1 -blockers do not completely reduce LUTS in patients.
The effects of different ␣ 1 -blockers have been intensively studied in isolated prostate tissues, and urodynamic effects in vivo are well characterized in patients and animal models (9, 10, 17, 18) . However, the effects of TXA2-R antagonists in prostate tissue are unknown to date. Picotamide is a platelet aggregation inhibitor. Its main mechanism of action is considered to be TXA2-R antagonism, but it also inhibits TXS (26) . However, some observations suggest an antivasoconstrictor effect independent of TXA2 inhibition/antagonism. Thus picotamide was shown to inhibit vascular contractions induced by phenylephrine and serotonin (5-HT) in a noncompetitive way (33) .
Here, we studied the effects of picotamide on prostatic smooth muscle contraction and compared its actions with those of other TXA2 antagonists. Furthermore, we assessed the expression of the thromboxane system in the human prostate.
METHODS

Human prostate tissue.
Human prostate tissues were obtained from patients undergoing radical prostatectomy for prostate cancer but without previous transurethral resection of the prostate (TURP). The research was carried out in accordance with the Declaration of Helsinki of the World Medical Association and has been approved by the Ethics Committee of the Ludwig-Maximilians University, Munich, Germany. Tissues in our study were exclusively taken from the periurethral zone. Most prostate tumors are located to the peripheral zone (25, 29) . Consequently, the extent of malignant areas (if any) in our samples may be neglected. Tissue samples did not exhibit histological signs of neoplasia, cancer, or inflammation. Samples were taken without any additional delay directly after prostatectomy and subsequent macroscopical pathological examination. Organ bath studies were performed immediately after sampling, while samples for fluorescence stainings were shock frozen in liquid nitrogen and stored at Ϫ80°C.
Tension measurements. Prostate strips (6 ϫ 3 ϫ 3 mm) were mounted in 10-ml aerated (95% O 2-5% CO2) tissue baths (Föhr Medical Instruments, Seeheim, Germany), containing KrebsHenseleit solution (37°C, pH 7.4). Preparations were stretched to 0.5 g and left to equilibrate for 45 min. In the initial phase of the equilibration period, spontaneous decreases in tone are usually observed. Therefore, tension was adjusted three times during the equilibration period, until a stable resting tone (0.5 g) was attained. After the equilibration period, maximum contraction induced by 80 mM KCl (Krebs-Henseleit solution where NaCl was exchanged by KCl) was assessed. Subsequently, chambers were washed three times with Krebs-Henseleit solution for a total of 30 min. Cumulative concentration response curves for U46619, norepinephrine, or phenylephrine were created after addition of TXA2-R antagonists or solvent [dimethylsulfoxide (DMSO)]. Frequency response curves induced by electric field stimulation (EFS) were created before and after addition of antagonists or DMSO. Antagonists or DMSO were applied 45 min before concentration or frequency response curves. Concentrations producing the half-maximal responses (EC 50 values) for contractile agonists were calculated using GraphPad Prism 6 (GraphPad Software, La Jolla, CA).
Immunofluorescence. Human prostate specimens, embedded in optimal cutting temperature compound, were snap frozen in liquid nitrogen and kept at Ϫ80°C. Sections (8 m) were cut in a cryostat and collected on microscope slides (Superfrost). Sections were postfixed in methanol at Ϫ20°C and blocked in 1% bovine serum albumin before incubation with primary antibody overnight at room temperature. For double labeling, following primary antibodies were used (if not other stated, all from Santa Cruz Biotechnology, Santa Cruz, CA): rabbit anti-TXA2-R (sc-30036), goat anti-TXA2-R (sc-31261), goatanti TXS (sc-79183), mouse anti-TXS (Tü-300; sc-59395), mouse anti-pan-cytokeratin (C11; sc-8018), mouse anti-prostate-specific antigen (PSA; A67-B/E3; sc-7316), mouse anti-calponin 1/2/3 (G-10) (sc-136987), and rabbit anti-␣-smooth muscle actin (␣-SMA; Thermo Scientific, Waltham, MA). Binding sites were visualized using Cy3-and Cy5-conjugated secondary antibodies [goat anti-mouse, AP124C; Millipore (Billerica, MA); and goat anti-rabbit, ab6564; Abcam (Cambridge, UK)]. Nuclei were counterstained with DAPI (Invitrogen, Camarillo, CA). Immunolabeled sections were analyzed using a laser scanning microscope (Leica SP2, Wetzlar, Germany). Fluorescence was recorded with separate detectors. Control stainings without primary antibodies did not yield any signals.
Drugs and solutions. Picotamide [4-methoxy-N,N=-bis(pyridin-3-ylmethyl)isophtalamide] is a combined competitive antagonist of the TXA2-R and inhibitor of TXS (20, 26) . Seratrodast [AA2414, 7- Aqueous stock solutions of phenylephrine and norepinephrine (10 mM) were freshly prepared before each experiment. U46619, picotamide, and L-665,240 were obtained from Enzo Life Sciences (Lörrach, Germany), seratrodast was obtained from Tocris (Bristol, UK), and phenylephrine and norepinephrine were obtained from Sigma (Munich, Germany). Concentrations of picotamide, L-665,240, and seratrodast were based on data from studies of platelets and vessels (13, 14, 19, 20, 31) .
Statistical analysis. Data are presented as means Ϯ SE with the indicated number (n) of experiments. Two-tailed student t-test was used for paired or unpaired observations. P Ͻ 0.05 were considered statistically significant.
RESULTS
U46619-induced contraction.
The stable TXA2 analog U46619 induced concentration-dependent contractions of human prostate strips (Fig. 1 ). U46619-induced contractions were significantly inhibited by picotamide (300 M), seratrodast (3 M), and L-665,240 (3 M; Fig. 1 ). As different volumes of solvent (DMSO) had to be applied in control panels, EC 50 values varied between the three separate series of each antagonist ( Table 1) . Inhibition of U46619-induced contraction by picotamide was observed at each applied concentration of U46619 (P Ͻ 0.05 for picotamide vs. DMSO; Fig. 1A ). The EC 50 for U46619 was significantly increased by picotamide (Table 1) man prostate strips, according to their expected function as TXA2-R antagonists.
EFS-induced contraction. EFS induced frequency-dependent contractions of human prostate strips (Fig. 2) . EFS-induced contractions were significantly inhibited by picotamide but not by solvent (DMSO; Fig. 2A ). In contrast, seratrodast or L-665,240 was without effect on EFS-induced contraction (Fig. 2, B and C) . Inhibition of EFS-induced contraction by picotamide was observed at each tested frequency (P Ͻ 0.001 between picotamide and DMSO at 2 Hz, P Ͻ 0.0001 at 4 Hz, P Ͻ 0.001 at 8 Hz, P Ͻ 0.0.0001 at 16 Hz, and P Ͻ 0.001 at 32 Hz). At frequencies from 2 to 16 Hz, contractions were virtually abolished by picotamide. This shows that TXA2 is not released as a contractionmediating neurotransmitter, as seratrodast and L-665,240 did not inhibit EFS-induced contractions. Therefore, inhibition of EFSinduced contraction by picotamide has to be explained by TXA2-R-independent mechanisms.
Adrenergic contraction. The ␣ 1 -adrenergic agonist phenylephrine and norepinephrine induced concentration-dependent contractions of human prostate strips (Fig. 3) . Phenylephrineand norepinephrine-induced contractions were significantly inhibited by picotamide (Fig. 3 ). Significant inhibition of phenylephrine-induced contraction was observed at 0.3 M phenylephrine (P Ͻ 0.05 for picotamide vs. DMSO), 1 M (P Ͻ 0.001), 3 M (P Ͻ 0.001), 10 M (P Ͻ 0.01), 30 M (P Ͻ 0.05), and 100 M (P Ͻ 0.05; Fig. 3A ). Significant inhibition of norepinephrine-induced contraction was observed at 3 M norepinephrine (P Ͻ 0.05 for picotamide vs. DMSO), 10 M (P Ͻ 0.01), and 30 M (P Ͻ 0.05; Fig. 3B ). At 100 M norepinephrine, contraction was still effectively reduced (P Ͻ 0.1). EC 50 values for phenylephrine and norepinephrine were significantly increased by picotamide (Table 2 ). Thus picotamide inhibits ␣ 1 -adrenoceptor-induced prostate smooth muscle contraction, besides TXA2-induced contraction.
Interaction of TXA2-R with ␣ 1 -adrenoceptors. Phenylephrine-induced contraction of prostate strips was maximal at 100 M. After submaximal contraction with 10 M phenylephrine, addition of U46619 (3 M) further increased tension of prostate strips (Fig. 4A) . Tension after simultaneous application of 10 M phenylephrine and 3 M U46619 was similar to the maximal phenylephrine-induced contraction, while tension induced by 10 M phenylephrine alone was 61 Ϯ 7% of the maximal phenylephrine-induced contraction (P Ͻ 0.05 for 10 M phenylephrine vs. 10 M phenylephrine ϩ 3 M U46619; P Ͻ 0.001 for 10 M phenylephrine vs. 100 M phenylephrine; Fig. 4B ). This shows that TXA2 may increase prostate smooth muscle tone to maximum if ␣ 1 -adrenergic tension is low.
TXA2-R expression. Fluorescence labeling of prostate sections revealed immunoreactivity for TXA2-Rs in the prostate stroma and in epithelial cells of prostate glands (Fig. 5) . In double fluorescence stainings, this immunoreactivity colocalized with immunoreactivity for the smooth muscle markers calponin and ␣-SMA in the prostate stroma (Fig. 5) . Immunoreactivity for calponin was strongly confined to stromal cells (Fig. 5) . Immunoreactivity for ␣-SMA was strong in the stroma but weak in epithelial cells (Fig. 5) . Furthermore, immunoreactivity for TXA2-R colocalized with immunoreactivities for the epithelial marker, pan-cytokeratin, and PSA (Fig. 5) . While immunoreactivity for pan-cytokeratin was strongly confined to prostate glands, immunoreactivity for PSA was observed in glands and in stromal cells (Fig. 5) . Together, this demonstrates that TXA2-Rs are expressed by smooth muscle cells in the stroma and by epithelial cells in glands.
TXS expression. Fluorescence labeling of prostate sections revealed immunoreactivity for TXS in the prostate stroma and in epithelial cells of prostate glands (Fig. 6) . In double immunofluorescence stainings, this immunoreactivity colocalized with immunoreactivity for calponin and ␣-SMA in the prostate stroma (Fig. 6) . Furthermore, immunoreactivity for TXS colocalized with immunoreactivities for pan-cytokeratin, PSA, and TXA2-R (Fig. 6) . Colocalization of TXS with TXA2-R was observed in the prostate stroma and in epithelial cells of prostate glands (Fig. 6) . Together, this demonstrates that TXS is coexpressed with TXA2Rs in stromal smooth muscle cells and in epithelial cells of glands.
DISCUSSION
Inhibition of prostate smooth muscle contraction is an important strategy for the treatment of LUTS in patients with BPS (2, 3, 17, 27, 28) . Administration of ␣ 1 -blockers causes relaxation of prostate smooth muscle and reduces bladder outlet obstruction (BOO) and symptoms (2, 3, 17, 27, 28) . Although treatment with ␣ 1 -blockers belongs to the first-line therapies, their efficacy may be limited (9, 10, 16, 18) . In fact, a complete reversal of all symptoms is often not obtained, suggesting that nonadrenergic factors contribute to prostate smooth muscle tone in addition to ␣ 1 -adrenoceptors (9, 10, 16, 18) . Our present findings show that picotamide, considered to be mainly a TXA2-R antagonist, was capable of inhibiting both adrenergic and thromboxane-induced contraction of human prostate smooth muscle.
We confirmed the presence of TXS and TXA2-R in stromal and epithelial cells of the human prostate. While ␣ 1 -adrenergic contraction and effects of ␣ 1 -blockers have been intensively studied in patients and experimental models, the effects of TXA2-R antagonists have, to the best of our knowledge, not been studied to date (9, 10, 16 -18) . We tested the effects of three different TXA2-R antagonists on contraction of human prostate tissues. Not surprisingly, all of them inhibited U46619-induced contractions. However, seratrodast and L-655,240 did not modulate EFS-induced contractions, suggesting that if TXA2 contributes to prostatic smooth muscle tone, it may act as a paracrine mediator and not as a neurotransmitter. Surprisingly, picotamide almost abolished EFS-induced contractions, which are primarily mediated by neuronal release of norepinephrine and activation of postsynaptic ␣ 1 -adrenoceptors (3, 17) . Ablation of EFS-induced contraction by picotamide may therefore be explained by inhibition of adrenergic contraction, as picotamide markedly reduced phenylephrine-and norepinephrine-induced contractions. Thus, in the human prostate, picotamide acts not only as an antagonist for the TXA2-R but also for ␣ 1 -adrenoceptors.
The stable TXA2 analog U46619 has been shown to induce contraction of prostate smooth muscle by stimulation of the TXA2-R and consequent activation of intracellular Rho kinaseand calcium/calmodulin-dependent pathways (32) . Both mechanisms have also been shown to be employed by ␣ 1 -adrenoceptor agonists (3, 7, 17) , suggesting that TXA2-Rs and ␣ 1 -adrenoceptors in the human prostate share the same effectors to mediate contraction (32) .
In male patients with LUTS, ␣ 1 -blockers reduce symptoms by 30 -50% (9, 10, 16, 18) . Since clinical studies, where ␣ 1 -blockers were compared with placebos, noted considerable improvements (between 10 -40%) by placebos (9, 10, 16, 18) ; this suggests a modest effect of the drugs. It is widely accepted that smooth muscle tone may be an important determinant of BOO in patients with BPS (2, 27, 28) . We propose that the limited effect of ␣ 1 -blockers can be explained by TXA2-mediated smooth muscle contraction in the prostate. Thus TXA2 may raise prostate smooth muscle tone even under therapy with ␣ 1 -blockers. In our present study, we simulated this situation by application of a low dose of phenylephrine, which induces only submaximal contraction. This may resemble reduced ␣ 1 -adrenergic prostate tone during therapy with ␣ 1 -blockers. After additional application of U46619 to these strips, full contraction and raising of the incomplete adrenergic tone to the maximum tone were observed. This suggests that TXA2-Rs and ␣ 1 -adrenoceptors act in concert and that even in the presence of ␣ 1 -adrenoceptor blockade, TXA2 may contract prostate smooth muscle. Therefore, it may be speculated that blocking TXA2-R and ␣ 1 -adrenoceptors simultaneously may be a more effective way to block prostatic tone and associated LUTS than ␣ 1 -blockers alone.
Picotamide inhibited contractions induced not only by U46619 but also by norepinephrine, phenylephrine, and EFS. In contrast, seratrodast and L-655,240, which are selective TXA2-R antagonists, only inhibited U46619-induced contractions.
Picotamide does not only act on TXA2-Rs but additionally inhibits TXS (11, 21) . In our organ bath experiments, the effects of endogenous TXA2 produced by TXS may not be relevant, as a defined basal tension was adjusted before tissues were challenged with exogenous agonists or by EFS. Inhibition of phenylephrine-induced smooth muscle contraction has been previously reported from rabbit aortic rings, in addition to 5-HT-and TXA2-mediated vasocontraction (33) . While picotamide, seratrodast, and L-665,240 competitively antagonize the TXA2-R, antagonism of ␣ 1 -adrenoceptors and serotonin receptors by picotamide is noncompetitive (33) .
The affinities of TXA2-R antagonists to the receptor may differ (13, 14, 19, 20, 31) . For picotamide, seratrodast, and L-655,240, different K i values for competition of TXA2-R ligands have been reported, based on studies performed in thrombocytes, vessels, or other models (13, 14, 19, 20, 31) . Therefore, we used higher concentrations of picotamide, as of seratrodast and L-655,240. The volume of DMSO applied to control panels was correspondingly adapted. Although it may interfere with smooth muscle tone, DMSO is a common solvent used in organ bath studies. This may explain, why we observed a slight, but insignificant, reduction of EFS-induced contraction by DMSO in our picotamide experiments but not in our series with other antagonists. In addition, this may be responsible for lower contractions in our experiments showing the effects of picotamide on U46619. Despite the use of DMSO, the effects of picotamide were clear, and we did not compare contractions obtained with different volumes of DMSO.
Immunoreactivity for TXS was observed in stromal smooth muscle cells and in epithelial cells of glands, suggesting production of TXA2 in the stroma and glands. TXA2 from both sources may initiate stromal smooth muscle contraction. Thus, by production in the epithelium and stroma, paracrine actions on smooth muscle may occur throughout the stroma, including smooth muscle contraction by epithelium-derived TXA2. Vice versa, stroma-derived TXA2 may act on TXA2Rs in glands. This may point to new mechanisms of stromalepithelial interactions. Finally, strong expression of TXA2-R in the epithelium indicates additional, noncontractile functions of TXA2 in the prostate. However, these functions remain to be understood and were outside the focus of the present study.
For our study, we used prostate tissues from patients undergoing radical prostatectomy. These tissues were obtained from the periurethral zone, while most prostate tumors are located to the peripheral zone (25, 29) . Indeed, malignancy was not detected in our tissues upon macroscopic inspection during sampling. Patients undergoing radical prostatectomy mostly show prostate hyperplasia (1, 24) . Therefore, normal prostate tissue was not available for our study, and a comparison between hyperplastic and nonhyperplastic tissues was not possible. We assume that our findings may represent the conditions in the hyperplastic prostate, which is of utmost importance from a clinical point of view. Of note, the smooth muscle markers calponin and ␣-SMA were detectable by fluorescence staining in all investigated samples.
Together, urodynamic effects of picotamide in vivo appear possible. Picotamide has been tested in a number of clinical studies, which were performed in cardiovascular context (5, 6, 8, 12, 22) . In these studies, application of picotamide was without adverse events even with long-term use (5, 6, 8, 12, 22) . This should make it of interest to test urodynamic effects of picotamide in animal models with experimentally induced BOO, or even in patients with LUTS.
Conclusions. TXA2 induces contraction of prostate smooth muscle independently from ␣ 1 -adrenoceptors, but both TXA2-R and ␣1-adrenoceptors share common pathways when mediating contraction. Picotamide inhibits contraction of human prostate smooth muscle induced both by TXA2-R and ␣ 1 -adrenoceptor stimulation. It may be speculated that picota- mide may be as effective as ␣ 1 -blockers in patients with LUTS and may have effects also when the response to ␣ 1 -blockers is insufficient.
